AVAILABILITY OF NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT B-28 CLINICAL TRIAL TISSUE MICROARRAY RELEASE DATE: April 11, 2003 NOTICE: NOT-CA-03-022 National Cancer Institute (NCI) (http://www.nci.nih.gov) The National Cancer Institute, and the National Surgical Adjuvant Breast and Bowel Project (NSABP), announce a one time only opportunity for investigators from US and non-US academic centers to evaluate candidate markers on breast cancer specimens from a large clinical trial. Strong preclinical and pilot clinical supportive data must be provided in the proposal. The tissue microarray consists of specimens from 2,000 cases enrolled into the NSABP trial B-28. The B-28 trial assessed the worth of adding taxol to standard adriamycin cyclophosphamide regimen in the treatment of axillary node positive breast cancer. Therefore the tissue microarray set from B-28 is ideal for evaluating candidate predictive markers of taxol response/resistance. INQUIRIES: For further information and to receive the announcement for this competition, send your name and e-mail address to: Roger Aamodt, Ph.D. Chief, Resources Development Branch Cancer Diagnosis Program, NCI EPN 6035A, 6130 Executive Boulevard Rockville, MD 20892 Phone: 301 496-7147 FAX: 301 402-7819 E-mail: ra32u@nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |